This investment will support Genome Insight’s pursuit of bringing whole-genome based precision diagnostics to routine clinical care. Earlier this year, the company announced the launch of CancerVision, a test that utilizes whole genome sequencing to offer precise, timely, and medical relevant information that assists in making individualized healthcare decision in cancer. CancerVision integrates advanced bioinformatics and computational techniques to determine whole-genome mutational profiles of individual cancer patients. The information is analyzed and curated for physicians in an easy-to-use format that captures the most relevant and actionable insights for each patient.

"Genomic data has the potential to unlock a new era in healthcare. We envision a future where genomic information is integral to standard patient care," says Young Seok Ju, the Founder and CEO at Genome Insight.